All News
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE
Links:
Dr. John Cush RheumNow ( View Tweet)
Scleroderma – Thick and Thin (6.30.2023)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.
Read Article
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0
Links:
Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of systemic sclerosis is scleroderma, but less than 10% of SSc patients have sine scleroderma (ssSSc). A EUSTAR database review compared the manifestations and outcomes of ssSSC to limited cutaneous SSc and diffuse cutaneous SSc.
Read Article
Check SSc-ILD Patients on Nintedinib for Malnutrition
d
MedPage Today
During nintedanib treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
Read Article
Taiwan claims data analysis of 1,830 scleroderma (SSc) pts & 27,981 controls showed increased incidence of SSc hospitalized w/ heart failure of 3.5%, 5.3%, & 9.7% (at 3, 5, 10 yrs). SSc patients had an increased risk of HF (adjusted HR 3.26) https://t.co/4WcHfiTJVF https://t.co/rW3J5aQdlS
Links:
Dr. John Cush RheumNow ( View Tweet)
Scleroderma therapeutics: we’re actually getting some choices!
Christian Dejaco #EULAR2023 @RheumNow https://t.co/sW2FBY0RqS
David Liew drdavidliew ( View Tweet)
A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241 https://t.co/8ZlHJmETGA
Janet Pope Janetbirdope ( View Tweet)
Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing Y vs N immune suppression- there was no difference in FVC decline. Maybe not a long enough study, ? Chanelling bias scleroderma #lung #disease OP0239 @RheumNow #EULAR2023
Janet Pope Janetbirdope ( View Tweet)
Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality outcomes >700 pts - half had a DMARD after dx RheumNow #EULAR2023 OP0238 Targeted Rx improved esp RTX\TCZ findings V interesting results #GameChanger May change my Rx practice!
Janet Pope Janetbirdope ( View Tweet)
No new predictors for decline in #SSc lung function in ILD Progression of #scleroderma Lung disease is common - risks male, dcSSc, low FVC, Topo1 @RheumNow #EULAR2023, OP0236 @eular_org https://t.co/bTxTyLE8dZ
Janet Pope Janetbirdope ( View Tweet)
Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w
Janet Pope Janetbirdope ( View Tweet)
#Scleroderma activity index #SCTC has an initial validated tool that is associated with death and organ damage with moderate correlations, so it has some degree of face validity @RheumNow #EULAR2023 @eular_org #OP0235 https://t.co/RDekhr7d2e
Janet Pope Janetbirdope ( View Tweet)
Scleroderma has an activity index that is associated w future morbidity & mortality. I wonder re the weightings of diff clinical manifestations as scleroderma renal crisis could weigh similarly to ex elevated CRP & a less severe manifestation. OP0235 @RheumNow #EULAR2023 https://t.co/KkimHBDVpg
Janet Pope Janetbirdope ( View Tweet)
#ClinicalPearl Updated #scleroderma Rx recommendations OP0234 New recommendations included ILD, early dcSSc 20 vs prior 16 guidelines. And they recommend ??! Won’t release yet due to importance of wording which will be finalized soon EULAR2023 @RheumNow @eular_org https://t.co/lES6pqkgeT
Janet Pope Janetbirdope ( View Tweet)
Early Rx with immunosuppressives doesn’t seem to prevent ILD in #scleroderma ? Chanelling bias as dcSSc get more ILD, esp if active disease but in this side it didn’t make a difference #EULAR2023 @RheumNow OP0239 https://t.co/xt0mtpOpYl
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is Interferon Type1 Impt in #scleroderma? #EULAR2023 OP#0114 Interferon accelerated skin fibrosis in mouse model- 61 pts 1/3 dcSSc, 2/3 lcSSc had markers of INF-1 in blood vessels &skin - more in #diffuse #SSc ?Rx opportunity w available drugs? RCT needed @RheumNow @eular_org https://t.co/vZWjSY8jKg
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed:
- 1 in 10 people had AID in the last 20yrs
- socioeconomic, seasonal & regional disparities cd influence pathogenesis
- CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Juvenile and Adult-onset Scleroderma Differ
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
https://t.co/57OrgaUNqj https://t.co/Y2puN18ux0
Links:
Dr. John Cush RheumNow ( View Tweet)